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We compared the QuickVue Inﬂ  uenza test with PCR 
for diagnosing pandemic (H1N1) 2009 in 404 persons with 
inﬂ   uenza-like illness. Overall sensitivity, speciﬁ  city,  and 
positive and negative predictive values were 66%, 84%, 
84%, and 64%, respectively. Rapid test results should be 
interpreted cautiously when pandemic (H1N1) 2009 virus 
is suspected.
S
ince its emergence, the pandemic (H1N1) 2009 virus 
has spread rapidly throughout the world. To diagnose 
inﬂ  uenza at the point of care, many clinicians rely on com-
mercial rapid enzyme immunoassay tests, which are cur-
rently unable to differentiate between inﬂ  uenza A virus 
subtypes (1). Compared with PCR and viral culture, the 
sensitivity of rapid tests for seasonal inﬂ  uenza varies from 
70% to 90% in children and <40% to 60% in adults (2,3). 
The positive and negative predictive values (PPVs and 
NPVs) of rapid tests depend on the prevalence of inﬂ  uenza 
viruses among the population being tested (2,3). 
We compare PCR with a rapid inﬂ  uenza test to better 
characterize the diagnostic utility of the rapid test during 
the current pandemic. The QuickVue Inﬂ  uenza test (Quidel 
Corp., San Diego, CA, USA) detects inﬂ  uenza A and B 
viruses but does not distinguish between them. Clinicians 
may use the test in their ofﬁ  ces because it is waived from 
Clinical Laboratory Improvements Amendment require-
ments based on documentation that test results by persons 
without formal laboratory training are in concordance with 
results by trained laboratorians.
The Study
The California Department of Public Health (CDPH) 
supplied QuickVue Inﬂ  uenza test kits to clinicians partici-
pating in the Centers for Disease Control and Prevention 
(CDC) Sentinel Provider Inﬂ  uenza Surveillance Program. 
Sentinel providers performed the QuickVue Inﬂ  uenza test 
on a ﬁ  rst respiratory specimen obtained from outpatients 
with inﬂ  uenza-like illness (fever >100°F and cough and/or 
sore throat) using the foam swab provided by QuickVue. 
Clinicians collected a second respiratory specimen using a 
sterile Dacron swab that was stored in viral transport media 
at 4°C for <72 hours before shipment to CDPH. Sentinel 
providers recorded information about patient demograph-
ics, symptoms, and QuickVue test results on a standardized 
specimen collection form.
At CDPH, specimens were tested by an inﬂ  uenza A 
universal real-time reverse transcription–PCR (rRT-PCR) 
assay with an analytical sensitivity (50% tissue culture 
infective dose /PCR input) of 0.51 for inﬂ  uenza A (4). If 
inﬂ  uenza A virus nucleic acid was detected, subtyping for 
human inﬂ  uenza A (H1 and H3) was performed. Speci-
mens negative for any subtype were tested for pandemic 
(H1N1) 2009 by using a rRT-PCR detection panel provid-
ed by CDC. For all PCR testing, a cycle threshold (Ct, the 
cycle count at which ampliﬁ  ed product yielded a detectable 
ﬂ  uorescent signal) <40 was interpreted as positive. Sensi-
tivity, speciﬁ  city, predictive values, likelihood ratios, and 
posttest probabilities were estimated according to standard 
deﬁ  nitions (5). This activity was reviewed by the California 
Committee for the Protection of Human Subjects and de-
termined to be a public health response that did not require 
institutional review board approval.
From May 4 to November 19, 2009, a total of 703 
specimens were collected, including swabs from nares 
(293), nasopharynx (178), oropharynx (3), a mixture of 
sites (227), and unspeciﬁ  ed sites (2). During this same peri-
od, statewide surveillance detected pandemic (H1N1) 2009 
in 30%–50% of patients with inﬂ  uenza-like illnesses tested 
and 92%–100% of inﬂ  uenza viruses identiﬁ  ed.
The median age of patients with inﬂ  uenza-like illness 
was 19 years (range 0–80 years). The median time from 
illness onset to specimen collection was 2 days (range 0–20 
days). Of 703 specimens tested, 417 came from patients 
who had positive PCR results for inﬂ  uenza; 13 had sea-
sonal inﬂ  uenza A subtypes, including 9 A/H1 and 4 A/H3; 
and 404 patients had pandemic (H1N1) 2009. Of these 404 
patients, 266 (66%) had positive results and 138 (34%) had 
negative results by rapid antigen test (Table). Of 299 pa-
tients in which pandemic (H1N1) 2009 was not detected 
by PCR, 49 (16%) were positive and 250 (84%) were nega-
tive by the rapid antigen test. The prevalence of pandemic 
(H1N1) 2009 infection in all samples was 57%. The over-
all sensitivity, speciﬁ  city, PPV, and NPV of the QuickVue 
Inﬂ   uenza Rapid Test for 2009 (H1N1) inﬂ  uenza  when 
compared with PCR, regardless of the timing of collec-
tion, were 66%, 84%, 84%, and 64%, respectively, with a 
positive test result increasing the posttest probability from 
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57% to 84% and a negative test result decreasing it to 36%. 
The sensitivity, speciﬁ  city, PPV, and NPV of the rapid test 
compared to PCR for persons <18 years of age were 68%, 
80%, 87%, and 56%, respectively, and for persons >18 
years were 64%, 86%, 82%, and 69%, respectively.
Ct values were available for 389 specimens in which 
pandemic (H1N1) 2009 virus was detected by PCR; of 
these, the median inﬂ  uenza A PCR Ct value was 26 for 
135 specimens with a negative rapid test result and 21 for 
254 specimens with a positive rapid test result (p<0.0001); 
samples with higher viral loads were more likely to be posi-
tive by rapid test (Figure). Even so, ≈25% of PCR-positive, 
rapid test–negative specimens had Ct values <23.
Other smaller studies have found comparable sensitiv-
ities, but higher speciﬁ  cities, for rapid antigen tests for pan-
demic (H1N1) 2009. In a CDC study of 45 samples provid-
ed by state laboratories, the sensitivity of all rapid tests was 
40%–69%, including 69% for QuickVue Inﬂ  uenza A+B 
(6). Others have found the QuickVue rapid tests to have 
sensitivities of 51%–63% and speciﬁ  cities of 99%–100% 
(7–9). During a large cluster of school outbreaks in New 
York, NY, USA, the sensitivity and speciﬁ  city of the Bi-
nax NOW (Inverness Medical International, Bedford, UK) 
rapid test were 17.8% and 93.6%, respectively (10). As we 
found, positive rapid antigen test results in other studies 
also appear to correlate with higher concentrations of pan-
demic (H1N1) 2009 virus (6,11,12).
Conclusions
Our ﬁ  ndings illustrate the challenges clinicians face 
during the current pandemic. Because clinical symptoms of 
pandemic (H1N1) 2009 are nonspeciﬁ  c, deﬁ  nitive diagno-
sis requires conﬁ  rmatory PCR testing, which, when avail-
able, often requires several days between specimen col-
lection and reporting of results. Rapid antigen tests are the 
only current option for screening and diagnosis at the point 
of care. Current CDC guidelines recommend that high-
risk and hospitalized infected patients be treated promptly 
with antiviral drugs and managed by using speciﬁ  c infec-
tion control precautions (13). Given the frequency of error 
found in this study, pandemic (H1N1) 2009 cannot be ex-
cluded solely because of a negative rapid antigen test result. 
Likewise, false-positive results, which would be expected 
to increase when the prevalence of inﬂ  uenza as a cause of 
inﬂ  uenza-like illness decreases, may result in unwarranted 
treatment and infection control measures that can be labor 
and resource intensive. Although rapid antigen tests are re-
ported to have high speciﬁ  city for seasonal inﬂ  uenza, our 
ﬁ  ndings conﬂ  ict with previous assumptions that rapid an-
tigen tests are sufﬁ  ciently speciﬁ  c to guide decisions about 
withholding antiviral treatment or chemoprophylaxis for 
pandemic (H1N1) 2009 (2).
A difference in swab types between rapid and PCR 
testing might have affected sensitivity of the rapid test re-
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Table. Performance of rapid antigen test compared with PCR in the diagnosis of pandemic (H1N1) 2009* 
Parameter  All specimens  Patient age <18 y†  Patient age >18 y† 
No. rapid test positive, PCR positive 266 131 130
No. rapid test positive, PCR negative 49 19 28
No. rapid test negative, PCR positive 138 62 74
No. rapid test negative, PCR negative 250 78 166
Total no. tested 703 290 398
Prevalence of PCR positives in sample 0.57 0.67 0.51
Sensitivity 0.66 0.68 0.64
Specificity 0.84 0.80 0.86
Positive predictive value 0.84 0.87 0.82
Negative predictive value 0.64 0.56 0.69
Positive likelihood ratio (95% CI) 4.0 (3.1–5.2) 3.5 (2.3–5.3) 4.4 (3.1–6.3)
Posterior probability of positive test result (95% CI) 0.84 (0.81–0.88) 0.87 (0.82–0.91) 0.82 (0.76–0.87)
Negative likelihood ratio (95% CI) 0.41 (0.35–0.47) 0.40 (0.32–0.50) 0.42 (0.35–0.51)
Posterior probability of negative test result (95% CI) 0.36 (0.32–0.39) 0.44 (0.39–0.50) 0.31 (0.27–0.35)
*CI, confidence interval. 
†Does not include results for 15 case-patients where age was not recorded. 
Figure. Comparison of cycle threshold (Ct) values for pandemic 
(H1N1) 2009 real-time reverse transcription–PCR-positive 
specimens (n = 389) with negative (neg) and positive (pos) rapid 
antigen test (RT) results. Solid lines represent median value for Ct.sults. Likewise, although inﬂ  uenza B virus was detected in 
only 9 (0.09%) of 10,367 specimens during the 7.5 months 
of statewide surveillance, some rapid test results may have 
been interpreted as falsely positive due to infection with 
inﬂ  uenza B.
In conclusion, we found the QuickVue inﬂ  uenza test 
had suboptimal sensitivity and speciﬁ  city for the detection 
of pandemic (H1N1) 2009 during a period of increased 
prevalence in California. This ﬁ  nding suggests that rapid 
test results that may lead to changes in clinical management 
or public health intervention should be conﬁ  rmed  with 
PCR. A strength of our study is its reﬂ  ection of typical test-
ing practices in outpatient settings and the need for recon-
sideration of the clinical application of rapid test results. 
The development of more accurate point-of-care tests for 
seasonal and pandemic (H1N1) 2009 infection is urgently 
needed.
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